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Background: There is signiﬁ  cant variation in Amphotericin B (AMB) efﬁ  cacy and relapses in 
antimony unresponsive visceral leishmaniasis (VL) cases over a period of time (10–15 years). 
Keeping in mind the above mentioned view this study was undertaken with an objective to 
assess the magnitude of cure and relapse rates of AMB in the treatment of antimony unrespon-
sive VL cases.
Methods: In a controlled, randomized nonblinded clinical trial, we evaluated the cure and 
relapse rate of Amphotericin B deoxycholate as compared to pentamidine. A total of 82 sodium 
stibogluconate (SSG) unresponsive and parasitologically conﬁ  rmed VL cases were included in 
this study and randomized into two groups, test (Amphotericin B) and control (Pentamidine). 
Both the groups were treated with recommended dosages (as per World Health Organization 
guidelines) of respective medicines. All the patients were followed up on 1st, 2nd, and 6th 
month after end of treatment.
Results: Apparent cure rate in the Amphotericin B group was found to be 95% (39/41) com-
pared with 83% (34/41) in the Pentamidine group, which shows signiﬁ  cant statistical difference 
(p = 0.05). The ultimate cure rate was found 92% (38/41) in the Amphotericin B group compared 
to 73% (30/41) in the Pentamidine group, which shows a signiﬁ  cant statistical difference (Yates 
corrected chi-square = 4.42, p = 0.04). Similarly, signiﬁ  cant statistical difference was observed 
in the relapse rate of the Amphotericin group compared to the Pentamidine group (p = 0.03).
Conclusions: AMB may still be the drug of choice in the management of resistant VL cases 
in Bihar, India. This is due to its consistent apparent cure rate (95%), low relapse rate (2.5%), 
and cost effectiveness compared with other available antileishmanial drugs. It is a safe drug 
even in case of pregnancy. Efforts should be taken to form a future strategy so that this drug 
and coming newer drugs do not meet a similar fate as has happened to SSG and pentamidine 
over a span of 10–15 years.
Keywords: sodium stibogluconate, apparent cure rate, ultimate cure rate, relapse rate, 
Amphotericin B deoxycholate
Introduction
Visceral leishmaniasis (VL) (Kala-azar) is a disease caused by a protozoan parasite, 
Leishmania donovani and transmitted by the bite of sandﬂ  y vector Phlebotomus 
argentipes. It occurs in more than 80 countries in Asia, Africa, Southern Europe, 
and South America, with a total of 200 million people at risk.1,2 However 90% of the 
estimated 500,000 new symptomatic cases per year occur in just ﬁ  ve countries: India, 
Sudan, Bangladesh, Nepal, and Brazil.3 India contributes to about 40%–50% of the Therapeutics and Clinical Risk Management 2009:5 118
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world’s total cases, from which 90% are from Bihar State 
alone. Kala-azar remains a serious public health problem in 
Bihar.4 The present treatment scenario of Kala-azar in Bihar 
is extremely unsatisfactory. The rising trend of unrespon-
siveness to sodium stibogluconate (SSG) in Bihar has been 
reported as 35%–45%. This has resulted in loss of affordable 
drugs to the region and forced clinicians to use alternative 
antileishmanial drugs.5–7 Pentamidine isethionate was the ﬁ  rst 
drug tried as second-line treatment. This was widely used 
at district hospitals in endemic areas of Kala-azar in Bihar 
till three to four years ago. But due to diminishing efﬁ  cacy 
(80%) over a period of time, serious toxicity such as insulin-
dependent diabetes, and cardiac toxicity in addition to its cost 
limited its use.8–10 Further reviews reveal the quick decline of 
response rate of pentamidine from  95% in the early 1980s 
to  70% a decade later.11,12 Numerous oral agents have been 
tested and discarded.13–15 Several combination therapies have 
also been tried. The result of therapeutic advances is milt-
efosine, an oral drug which seems to be a step in the right 
direction as shown by multicenter clinical trials in India.16 
Many other injectable/oral drugs are in trial stages. Presently 
Amphotericin B (AMB) is the only available alternative treat-
ment of choice in the Indian Government set-up in Bihar. 
But unfortunately signiﬁ  cant variation in AMB efﬁ  cacy was 
reported in antimony unresponsive cases over a period of 
time. Prior conducted studies have reported efﬁ  cacy in the 
range of 98%–100%.17–19 Further review of literature reveals 
that the AMB efﬁ  cacy has fallen to 90%–93% in India as 
well as in other parts of the world.20,21 Recent reviews reveal 
a cure rate of about 96%–97%, at the sixth month in either 
daily or alternate day infusions.22,23 Earlier reviews advocated 
AMB as a ﬁ  rst-line drug in the treatment of both unrespon-
sive and fresh cases of Kala-azar.23 Keeping in view the 
burden of the disease in poorer sections of India, widespread 
emergence of drug resistance, recent availability of an oral 
drug (miltefosine) and the Indian Government commitment 
to eliminate Kala-azar, the present study was undertaken to 
assess the magnitude of cure rate and relapse rate of AMB 
in the treatment of antimony unresponsive Kala-azar cases 
in Bihar over a period of the last 15 years.
Materials and methods
Study sites
Rajendra Memorial Research Institute of Medical Sciences 
(RMRIMS) is situated at Patna, the capital of Bihar state 
of India on the banks of the holy river, Ganges. RMRIMS 
is a research institute that focuses on Kala-azar research 
and treatment. The Institute has 50-bed indoor and outdoor 
facilities and is a recognized specialized treatment centre 
for Kala-azar. Generally, patients are referred from vari-
ous primary health centers and district hospitals with their 
earlier treatment records to RMRIMS in cases of failure to 
respond to the ﬁ  rst-line drug SSG at the periphery level. 
They were screened for inclusion and exclusion criteria of 
the trial at the time of attending the outpatient department 
(OPD). They were included in the study after fulﬁ  lling the 
inclusion and exclusion criteria. The present study was 
conducted in the year 2002 and follow-ups were completed 
in the same year.
Study patients
Patients unresponsive to SSG after full course of treat-
ment and having complaints of continued fever with rigor, 
hepato-splenomegaly, anorexia, anemia, loss of weight and 
attending RMRIMS OPD were the study patients. Their 
treatment records were veriﬁ  ed at the time of inclusion in 
the study group.
Treatment allocation
Treatment allocation was done by the biostatistician of the 
institute, who performed the allocation sequence using ran-
dom number tables and accordingly assigned the test and 
control group. The patients were sent to the indoor ward for 
further treatment with their allotted drug. Both groups of 
patients were treated after the hospitalization in RMRIMS 
indoor ward. Every patient completed the full course of 
assigned treatment.
Inclusion criteria
Patients of either sex aged between six to 60 years unrespon-
sive to SSG after a full course of treatment and having com-
plaints of continued fever with rigor, hepato-splenomegaly, 
anorexia, anemia, and loss of weight, sputum for acid-fast 
bacilli (AFB) and chest x-ray (PA-view) negative for tuber-
culosis or pneumonia, and demonstration of parasite in bone 
marrow (BM)/splenic(SPL) aspiration were the inclusion 
criteria.
Exclusion criteria
The conﬁ  rmed VL cases with partial dosages of SSG and 
with associated diseases like tuberculosis (TB), HIV/AIDS, 
and malaria, pregnant women, lactating mother, and diabet-
ics were not included in the study. The individuals who 
had past history of Kala-azar in last ﬁ  ve years and having 
Hb   6 g/dl, platelet count  50,000/mm3 with signiﬁ  cant 
abnormalities in liver and renal function tests were the 
exclusion criteria.Therapeutics and Clinical Risk Management 2009:5 119
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It is documented that if Hb   6 mg/dl and platelet 
count  50,000/mm3 there is a possibility of reduced efﬁ  cacy 
of the drug as well as its increased toxicity.24
Informed consent
Written informed consents for treatment and follow-up 
examinations were obtained from adult subjects and in case of 
minors, assent form was obtained from the legal representa-
tive of the subject prior to enrollment in the study.
Sample size
The hypothesis for the current study was to assess whether the 
cure and relapse rate of AMB was consistent as compared to 
pentamidine. We believed that the reported cure rate of AMB 
(based on the literature) would be 95% in the Amphotericin B 
group, while it would be about 75% in the Pentamidine 
group. Based on 90% power to detect a signiﬁ  cant differ-
ence (P = 0.05, two-sided) 100 patients were required for the 
study. To compensate for a 10% drop out, an optimum sample 
size for this clinical trial was 110 patients, which came to 
55 patients in each group. A total of only 82 (41 to each 
group) SSG-unresponsive and parasitologically conﬁ  rmed 
Kala-azar cases satisﬁ  ed inclusion and exclusion criteria 
and were included in the present study. The required sample 
size of 55 could not be achieved under the study because the 
pentamidine supply was stopped by the Government of India 
in the mean time.
The study intervention
The test group was treated with AMB (1 mg/kg body weight 
on alternate days in 5% dextrose over a period of 3–4 hours, 
intravenously for 15 days, starting with test dose) whereas the 
control group was treated with pentamidine (4 mg/kg body 
weight on alternate days with deep intramuscular injections 
for 15 days).
Investigations
Complete physical examination and clinical ﬁ  ndings were 
recorded in a pre-designed proforma. Laboratory investiga-
tions included a complete hemogram, blood biochemistry 
including electrolyte estimation and liver and kidney function 
tests. A chest radiogram and electrocardiogram were done. 
Splenic/BM aspiration was done when PT (prothrombin time) 
value was within normal limit and examined under micro-
scope for Leishman–Donovan bodies. In cases of VL, who 
had severe anemia (Hb   6 gm/dl), before excluding such 
patient from the study an effort was undertaken to increase 
their hemoglobin level by giving fresh blood transfusion as 
required. All laboratory investigations except blood sugar 
mentioned above were repeated on 14th day after the initia-
tion of treatment and at the end of treatment, while blood 
glucose was monitored on 0, 7, 14 days and at the end of 
treatment and during follow-up to observe the main complica-
tion of pentamidine, ie, diabetes mellitus. All vital signs (such 
as blood pressure, pulse, respiration rate, body temperature, 
etc.) were monitored daily. Speciﬁ  c clinical examinations 
(like measurement of spleen size and liver size) were done 
on every 7th day till the end of treatment. Parasitological 
examination was done before and after completion of therapy 
as well as at the end of six months follow-up in relapse cases. 
All the patients completed the full course of their assigned 
treatment and none were shifted to any other drug, even after 
minor toxicity which was managed accordingly. As soon 
as their blood investigation came to normal, treatment was 
restarted to complete the course. Those patients who were 
excluded from the study were referred to the Medical College 
for evaluation and further treatment. Rescue treatment was 
given in case of drug-induced toxicity and follow-up was 
carried out for six months after end of treatment.
Adverse reaction
Anaphylactic reactions ie, sweating, breathlessness, low 
pulse rate etc. were closely monitored clinically by the 
treating physician and staff nurses; recorded in the patient 
record sheet and such events were corrected simultaneously 
with 25% dextrose infusion and with antiallergic drugs in 
the Pentamidine group. The occurrence of adverse reactions 
was monitored and characterized for each of the regimens. 
Minor adverse reactions of both the groups were managed 
as per the standard normal procedures.
Follow-up
All the patients were followed up on the 1st, 2nd, and 6th 
month after end of treatment. Patients were instructed to 
report immediately in case of fever or other complications. 
The patients were called for follow up on due date and if 
they failed a postcard was sent on their home addresses. If 
they did not turn up, individual home visits were undertaken. 
Clinical examinations and routine laboratory investigations 
were done at each follow up. The BM aspiration was done 
for parasites at ﬁ  nal follow up in cases of relapse. All the 
patients completed six months follow up.
Apparent cure
Apparent cure was deﬁ  ned as absence of clinical signs and 
symptoms for Kala-azar as well as parasitologically negative Therapeutics and Clinical Risk Management 2009:5 120
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for Leishmania donovani parasite in their SPL/BM aspiration 
examination at the end of treatment.
Ultimate cure
Ultimate cure was deﬁ  ned as absence of clinical signs and 
symptoms for VL at the end of six months follow-up after 
end of treatment.
Relapse
Relapse was defined as reappearance of clinical signs, 
symptoms such as intermittent fever, enlargement of liver, 
enlargement of spleen and Leishmania donovani parasite 
in SPL/BM aspiration within a period of six months during 
follow-up.
Data analysis
Data were coded as numerical variables, entered into, and 
analyzed using the Epi-Info 6.0 database (Centre for Disease 
Control and Prevention, Atlanta, GA). Comparison of the 
two treatment groups and their baseline characteristics were 
done, using large sample test based on Gaussian distribution. 
Yates’s corrected Chi-square test was used for comparing the 
efﬁ  cacy and relapse rate of the two regimens.
Ethical considerations and consent
The study was approved by the scientiﬁ  c advisory commit-
tee and by the ethical committee of the Institute. Informed 
consent written in Hindi was obtained from each patient 
or guardian. If necessary, consent was verbally translated 
into the local language. Decision regarding management 
of patients were based on their clinical condition and were 
independent of the study.
Results
There were 120 patients assessed for eligibility in the present 
study, out of which 38 were excluded due to nonadherence 
to inclusion and exclusion criteria. These also included fresh 
cases of Kala-azar without history of any anti-Kala-azar 
treatment. Thus only 82 patients were randomly assigned 
to the intervention.
A total of 82 SSG unresponsive and parasitologically 
conﬁ  rmed VL cases were divided randomly into two groups 
before the initiation of the treatment. These were included 
in the study (41 receiving Amphotericin B and 41 receiving 
pentamidine). The clinical and laboratory characteristics of 
the patients of both the treatment groups were compared 
and there were no signiﬁ  cant differences (p   0.05) in the 
baseline characteristics of patients. The two groups were 
comparable (Table 1).
All the clinical and laboratory characteristics of patients 
in each group were compared at the end of the treatment. 
There was signiﬁ  cant changes in all clinical and laboratory 
characteristics in the Amphotericin B group except in blood 
sugar level, SGPT, creatinine, and Bilirubin, whereas in the 
Pentamidine group there was a signiﬁ  cant increase in blood 
sugar level. The two groups were comparable (Table 2).
Apparent cure rate in the Amphotericin B group was 
found to be 95% (39/41) compared with 83% (34/41) in the 
Pentamidine group, which shows a signiﬁ  cant statistical 
difference (p = 0.05). All the patients were followed up for six 
months after the end of treatment for recording relapse in two 
groups. In the Pentamidine group, four patients relapsed after 
2–4 months and were treated with AMB, whereas only one 
case relapsed after two months in the Amphotericin B group. 
The ultimate cure rate was found 92% (38/41) in the 
Amphotericin B group as compared to 73% (30/41) in the 
Pentamidine group at the end of follow-up, (Table 3) which 
shows a signiﬁ  cant statistical difference in the cure rate of 
AMB as compared to pentamidine (p = 0.04). Similarly, a 
statistically signiﬁ  cant difference was observed in the relapse 
rate of the Amphotericin B group compared to the Pentami-
dine group (p = 0.03).
In the course of follow-up, eight patients did not turn 
up for follow-up on their scheduled time. Of these, four 
came after receiving the postcards sent by the Institute. 







No. of patients 41 (M = 27, F = 14) 41 (M = 26, F = 15)
Age 18.3 ± 11.3 17.8 ± 11.0  0.05
Clinical
Weight (Kg) 30.02 ± 12.23 28.55 ± 12.28  0.05
Fever max (F) 101 ± 1.64 101.5 ± 1.57  0.05
Spleen size (cm) 7.79 ± 3.7 7.64 ± 3.3  0.05




4519 ± 2230 4004 ± 1741  0.05
Platelet count 
(100,000/mm3)
1.43 ± 0.59 1.29 ± 0.44  0.05
Hb (g/dl) 7.43 ± 1.63 6.94 ± 1.37  0.05
BSF (mg/dl) 75 ± 9.77 73 ± 8.26  0.05
BSPP (mg/dl) 93 ± 9.79 90 ± 9.45  0.05
Abbreviations: BSF, blood sugar (fasting); BSPP, blood sugar (post-parental);   WBC, 
white blood cell.Therapeutics and Clinical Risk Management 2009:5 121
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The remaining four were attended by the hospital staff by 
making a home visit to their houses for follow-up. All the 
patients completed the follow-up for six months.
In the Amphotericin B group, two patients developed mild 
elevation of creatinine and blood urea nitrogen (BUN). This 
was ascertained on the basis of their blood urea and creatinine 
investigation, which was performed after infusion of seven 
injections. Here the mild elevation is of grade-II, therefore 
the treatment was discontinued for a period of seven days 
and as soon as these changes became normal, AMB was 
restarted. After a full course of AMB, the patient was found 
apparently cured. On the other hand, ﬁ  ve patients developed 
hypoglycemia during the course of administering the drug in 
the Pentamidine group, which was treated with 25% dextrose 
infusion. It was ascertained on the basis of their blood sugar 
level, which was performed on 0, 7 days at the end of treat-
ment, and during follow-up. The data is presented in Table 1. 
Blood sugar was done to rule out the diabetes mellitus for the 
pentamidine regimen. No signiﬁ  cant abnormalities in liver 
function tests (serum glutamic pyruvic transaminase [SGPT], 
serum glutamic oxaloacetic transaminase [SGOT], serum 
Bilirubin) and renal function tests (blood urea and serum 
creatinine) were observed during the treatment (hence mid-
term evaluation of hematological and biochemical markers 
were not presented in Table 2). This was ascertained on the 
basis of their seventh day investigations after infusion during 
the treatment. Patients not apparently cured at the time of end 
of treatment were managed with a second course of AMB 
(rescue treatment) after an interval of 15 days. No deaths 
occurred in this trial.
Discussion
In the present study, the apparent cure rate of AMB was 
95% as compared to 83% in the pentamidine group, which 
shows a statistically signiﬁ  cant difference (p = 0.05). The 
apparent cure rate found under the present study was con-
sistent with the ﬁ  nding of even later conducted studies.12,22 
A study conducted in 2004 in Iran revealed the efﬁ  cacy of 
AMB was up to 100%.25 In another study conducted in 2007, 
the efﬁ  cacy of AMB was 97%.26 The ultimate cure rate of 
AMB was 92% without any signiﬁ  cant toxicity, which shows 
consistent efﬁ  cacy over a period of time as was observed in 
Table 2 The clinical and laboratory features of the treatment group after the end of treatment are presented
Amphotericin group Pentamidine group
Characteristics Before t/t After t/t p-value Before t/t After t/t p-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Clinical
Weight (Kg) 30.02 ± 12.23 36.3 ± 12.13  0.05 25.55 ± 12.28 26.96 ± 12.34  0.05
Fever max (F) 101 ± 1.64 97.9 ± 0.79  0.001 101.5 ± 1.57 98.4 ± 1.65  0.01
Spleen size (cm) 7.79 ± 3.7 2.05 ± 2.24  0.01 7.05 ± 2.9 2.73 ± 2.62  0.01
Liver size (cm) 2.56 ± 1.45 0.58 ± 0.91  0.01 2.8 ± 1.95 0.85 ± 1.15  0.01
Laboratory
WBC count (1000/mm3) 4519 ± 2230 6870 ± 2141  0.01 4004 ± 1741 6163 ± 2372  0.01
Platelet count (100,000/mm3) 1.43 ± 0.59 1.97 ± 0.59  0.01 1.29 ± 0.44 1.79 ± 0.48  0.01
Hb (g/dl) 7.43 ± 1.63 8.96 ± 1.41  0.01 6.94 ± 1.37 8.34 ± 1.31  0.01
BSF (mg/dl) 75 ± 9.77 76 ± 8.79  0.05 73 ± 8.26 77.45 ± 9.97  0.05
BSPP (mg/dl) 93 ± 9.79 94 ± 8.56  0.05 90 ± 9.45 95 ± 9.66  0.05
SGPT (units/L) 22.05 ± 16.96 18.96 ± 12.14  0.05 22.07 ± 5.62 19.38 ± 6.08  0.05
SGOT (units/L) 24.59 ± 5.61 19.09 ± 11.78  0.05 22.23 ± 6.88 17.69 ± 14.77  0.05
Creatinine (mg/dl) 0.67 ± 0.31 0.623 ± 0.28  0.05 0.65 ± 0.15 0.58 ± 0.21  0.05
Bilirubin (mg/dl) 0.6 ± 0.55 0.545 ± 0.3  0.05 0.55 ± 0.1 0.51 ± 0.12  0.05
Abbreviations: BSF, blood sugar (fasting); BSPP, blood sugar (post-parental); SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase; 
WBC, white blood cell.







a.  Apparent cure 95% (39/41) 83% (34/41) p = 0.05
b.  Ultimate cure 92% (38/41) 73% (30/41) p = 0.04
c.  Relapse rate 2.5% (1/39) 11.7% (4/34) p = 0.03Therapeutics and Clinical Risk Management 2009:5 122
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earlier studies.17,18,27 The ultimate cure rate of pentamidine 
was 73%, which may be the lowest ever reported in Bihar 
with signiﬁ  cant toxicity and increased relapse rate (12%), 
which is statistically signiﬁ  cant (p = 0.04). This ﬁ  nding was 
consistent with later conducted studies.10–12
The efﬁ  cacy of AMB and its lipid formulation was found 
equally effective28 whereas the efﬁ  cacy of AMB lipid formu-
lation was found as high as 100%20 which further declined 
to 92% in a study conducted in 2007.26
The average cost of a full course of AMB for adults comes 
to around US$69 which is much less than the cost of the lipid 
formulation (US$1120 for multiple infusions and US$560 
for single infusion).26 The cost of pentamidine is also much 
higher than a full course of AMB as it is imported. Initially 
in the 1950s, the cure rate of pentamidine was 99%29 but 
over a period of time in the year 1994, the reported cure rate 
of pentamidine was 82% in Bihar,30 which shows a gradual 
declining trend. The failure of pentamidine in the treatment of 
SSG-unresponsive Kala-azar cases posed a serious problem, 
because it was considered as a second-line drug, and was 
widely used in district hospitals in Kala-azar endemic areas 
of Bihar. Similarly, a statistically signiﬁ  cant difference was 
observed in the relapse rate of the Amphotericin B group 
(2.5%) compared to the Pentamidine group (11.7%) (p = 0.03). 
The relapse rate of AMB found in this study was slightly 
higher compared to an earlier conducted study (1.5%).31
Clinical and laboratory characteristics of the patients of 
both the treatment groups were compared and no statistically 
signiﬁ  cant difference (p   0.05) in the base line characteris-
tics were found. At the end of treatment signiﬁ  cant changes 
were observed in all clinical and laboratory characteristics in 
the Amphotericin B group except in blood sugar level, SGPT, 
creatinine, and Bilirubin whereas in the Pentamidine group, 
there was signiﬁ  cant increase in blood sugar level, which was 
remarkably consistent to several other studies conducted in 
Bihar.8,9 The relapse rate (2.5%) of the Amphotericin B group 
showed a signiﬁ  cant difference compared to (12%) the Pent-
amidine group. It indicates that the relapse rate of pentami-
dine is increasing over a period of time, which was similar 
to other study ﬁ  ndings.32 On the other hand, the relapse rate 
of AMB has remained consistent and within the acceptable 
range. In our study, we had found two patients (2/41) who 
developed mild elevation of creatinine and BUN and there-
fore treatment was discontinued for a period of seven days. As 
soon as these changes became normal, AMB was restarted. 
On the other hand, in the Pentamidine group, ﬁ  ve patients 
(5/41) developed hypoglycemia while administering the drug 
and were treated with 25% dextrose infusion intravenously. 
These ﬁ  nding were similar but not to the extent as reported 
earlier (7%–9% mortality and 60% toxicity with irreversible 
damage such as diabetes and cardiac toxicity leading to fatal 
arrhythmias) in other studies.23,27 The study incorporates the 
valuable use of AMB in the treatment of antimony unre-
sponsive Kala-azar cases. Several workers suggested using 
alternative drugs especially in cases of SSG-unresponsive and 
relapsing patients in its recommended dosage.17,32 Therefore 
treatment of Kala-azar with SSG and pentamidine has posed a 
major therapeutic challenge in combating Kala-azar in Bihar. 
Pentamidine acts against parasites by damaging kinetoplast 
DNA–mitochondrial complex.9 AMB on the other hand has 
the ability to inhibit biosynthesis of ergo sterol like steroid 
membrane sterols for both fungi and leishmania, thereby 
making it a potent antileishmanial drug.23
There is a need to discuss the therapeutic advances in 
VL to realize the difﬁ  culties occurring in the management 
of Kala-azar patients in Bihar. The newer drug, miltefos-
ine, appears to be a step forward for Kala-azar treatment, 
but the major drawbacks are its effect on the fetus, which 
restricts its use in childbearing age, during the course of 
treatment, and after two months of completion of therapy. 
Hence 30% among the female population of the childbearing 
age (15–45 yrs) will be excluded from treatment on these 
grounds. The other drawback is its unaffordable price.33 
Therefore it cannot be used as a mass outpatient treatment. 
On the other hand, an earlier study revealed that AMB could 
be effectively used during pregnancy with no harmful effects 
on the fetus.34 Another study on AIDS-associated VL reported 
a satisfactory response to AMB.21 Another study found that 
AMB efﬁ  ciently responded in patients unresponsive to 
pentamidine.35 More recently, a clinical trial of miltefosine 
vs AMB reported a cure rate (after six months follow-up) 
of 94% and 97%, respectively.36 Therefore, at present AMB 
has taken the lead in the treatment of Kala-azar.
From the days of Dr U.C. Brahamachari, various research-
ers hailing from Bihar have been continuously making efforts 
to conduct clinical trials of antileishmanials. Regular moni-
toring of efﬁ  cacy of various antileishmanials in the form of 
clinical trials have proved to be very beneﬁ  cial in addressing 
problems like unresponsiveness to SSG and pentamidine, 
which were considered the drug of choice 15 years ago. 
Introducing AMB as a ﬁ  rst-line drug in the national Kala-
azar elimination programme (2001) had signiﬁ  cant impact on 
the management of Kala-azar treatment in India. Insufﬁ  cient 
treatment from unqualiﬁ  ed providers and widespread lack of 
compliance emphasizes the need for intensive community 
education and better access to health services.Therapeutics and Clinical Risk Management 2009:5 123
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The results of this study suggest that AMB with an 
ultimate cure rate of 92% and with a relapse rate of 2.5% 
is still the only valuable drug of choice for the treatment of 
Kala-azar in Bihar. The issue of treatment of VL in develop-
ing countries is no longer limited to an individual patient. It 
is a public health problem considering that inadequate and 
ineffective therapy is fraught with emergence of secondary 
resistance. The issue of controlling VL also goes beyond 
development of new effective drug and therapies and imple-
mentation of vector control measures. The world has to face 
the problem of high costs of therapy squarely as control of 
VL cannot wait till the economic situation improves and 
social and cultural issues tackled.
The socioeconomic and cultural conditions of Bihar have 
a tremendous bearing on the prevalence of Kala-azar and its 
treatment. In practice most of the patients are expected to pur-
chase the drug by themselves which leads to low compliance to 
the therapy. Hence the Indian Government is supposed to initi-
ate steps to provide free/subsidized care and simultaneously 
ensure the regular availability of drug at peripheral level.
Considering the importance of AMB for Kala-azar 
patients, every effort should be taken to form a future strat-
egy so that this drug and coming newer drugs do not meet a 
similar fate to SSG and pentamidine in a span of 10–15 years. 
The consistent efﬁ  cacy of AMB over a period of time and 
relative cost effectiveness for treatment of SAG-unresponsive 
cases, even in pregnant women, in Bihar, show it to be a good 
choice. Generally, AMB is being used in public health system 
in Bihar even at periphery level (district hospital/primary 
health center) and the toxicity is being managed at the 
periphery level by the availability of pathological laboratory 
on public/private partnership in Bihar.
Conclusion
Amphotericin B appears to be a very efﬁ  cient drug in the 
armamentarium of clinicians for the treatment of SSG-
unresponsive Kala-azar cases. Thus the ﬁ  ndings of this study 
have important implication for health policy makers for the 
recent Kala-azar elimination programme (2001) in India.
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